Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma

Xijun Wang, Aihua Zhang, Hui Sun – 13 November 2012 – Hepatocellular carcinoma (HCC) is the commonest primary hepatic malignancy and the third most common cause of cancer‐related death worldwide. Incidence remains highest in the developing world and is steadily increasing across the developed world. Current diagnostic modalities, of ultrasound and α‐fetoprotein, are expensive and lack sensitivity in tumor detection. Because of its asymptomatic nature, HCC is usually diagnosed at late and advanced stages, for which there are no effective therapies.

Contrast‐enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma: Clinical and biological significance

Kota Sato, Shinji Tanaka, Yusuke Mitsunori, Kaoru Mogushi, Mahmut Yasen, Arihiro Aihara, Daisuke Ban, Takanori Ochiai, Takumi Irie, Atsushi Kudo, Noriaki Nakamura, Hiroshi Tanaka, Shigeki Arii – 13 November 2012 – Abnormal tumor vascularity is one of the typical features of hepatocellular carcinoma (HCC). In this study, the significance of contrast‐enhanced intraoperative ultrasonography (CEIOUS) images of HCC vasculature was evaluated by clinicopathological and gene expression analyses. We enrolled 82 patients who underwent curative hepatic resection for HCC with CEIOUS.

Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis

Chiung‐Kuei Huang, Soo Ok Lee, Kuo‐Pao Lai, Wen‐Lung Ma, Tzu‐Hua Lin, Meng‐Yin Tsai, Jie Luo, Chawnshang Chang – 13 November 2012 – Transplantation of bone marrow mesenchymal stem cells (BM‐MSCs) has been considered as an alternative therapy, replacing liver transplantation in clinical trials, to treat liver cirrhosis, an irreversible disease that may eventually lead to liver cancer development. However, low survival rate of the BM‐MSCs leading to unsatisfactory efficacy remains a major concern.

Subscribe to